Key result
Elevated CTI is linked to ~83% higher cardiometabolic multimorbidity risk, outperforming TyG.
Why the study?
Does the C-reactive protein-triglyceride-glucose index (CTI) improve the prediction of cardiovascular metabolic multimorbidity (CMM) risk compared with the triglyceride-glucose (TyG) index in adults aged ≥45 years?
Cohort (n=8,487)
Yes
Does the C-reactive protein-triglyceride-glucose index (CTI) improve the prediction of cardiovascular metabolic multimorbidity (CMM) risk compared with the triglyceride-glucose (TyG) index in adults aged ≥45 years?
Answers are grounded in this paper and cite their sources.
Integrating C-reactive protein with the triglyceride-glucose index (CTI) independently predicts 9-year cardiovascular metabolic multimorbidity risk and modestly improves discrimination compared with the TyG index alone.
Background Cardiovascular Metabolic Multimorbidity (CMM), a leading global cause of mortality, lacks evidence on the predictive utility of the novel C-reactive protein-triglyceride-glucose index (CTI), which integrates insulin resistance and inflammation. This study compared CTI with the established Triglyceride-Glucose (TyG) index in predicting CMM risk. Methods A cohort of 8,487 adults aged ≥45 from the CHARLS database (2011–2020) was analyzed. Over nine years, CMM events were tracked. Cox regression, restricted cubic spline (RCS), and ROC curve analyses assessed associations between TyG, CTI, and CMM risk. Subgroup analyses evaluated population-specific variations. Results Among participants, 1,030 (12.14%) developed CMM. Unadjusted Cox models showed TyG (HR = 1.89, 95%CI 1.73–2.07, P < 0.001) and CTI (HR = 1.83, 95%CI 1.70–1.97, P < 0.001) predicted CMM; adjusted models confirmed persistence. A dose–response association was observed for both CTI and TyG with CMM risk. In fully adjusted models, the overall dose–response trend remained similar. ROC analysis favored CTI (higher AUC). Subgroup analyses indicated TyG’s association varied by sex, smoking, and hypertension ( P < 0.05), while CTI’s association differed by age, sex, and hypertension ( P < 0.05). Conclusions Elevated CTI independently correlates with increased CMM risk, demonstrating superior predictive accuracy over TyG. Its linear association highlights potential clinical utility for early CMM risk stratification.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) conducted a cohort in Cardiovascular Metabolic Multimorbidity (CMM) risk (n=8,487). C-reactive protein-triglyceride-glucose index (CTI) vs. Triglyceride-Glucose (TyG) index / Lower quartiles (Q1) was evaluated on Incident Cardiovascular Metabolic Multimorbidity (CMM, defined as having two or more of heart disease, diabetes, and stroke) (HR 1.83, 95% CI 1.70-1.97, p=<0.001). Elevated C-reactive protein-triglyceride-glucose index (CTI) independently predicted cardiovascular metabolic multimorbidity risk and outperformed TyG.
Synapse has enriched 10 related papers. Consider them for comparative context: